Ocular Therapeutix (NASDAQ:OCUL) Releases Earnings Results, Misses Estimates By $0.05 EPS

Ocular Therapeutix (NASDAQ:OCUL) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05), Zacks reports. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million.

Ocular Therapeutix Stock Up 9.6 %

Shares of NASDAQ OCUL opened at $6.50 on Wednesday. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -4.92 and a beta of 1.22. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix has a 12 month low of $4.06 and a 12 month high of $11.78. The stock has a 50-day moving average price of $7.81 and a two-hundred day moving average price of $8.89.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $17.00.

Insider Activity

In other Ocular Therapeutix news, insider Donald Notman sold 11,119 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total value of $86,839.39. Following the completion of the transaction, the insider now directly owns 193,444 shares in the company, valued at approximately $1,510,797.64. This trade represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Pravin Dugel sold 21,475 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares of the company’s stock, valued at $24,184,584.66. This represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,895 shares of company stock worth $283,772. Corporate insiders own 3.50% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.